XML 73 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Additional Information (Details)
1 Months Ended 12 Months Ended 24 Months Ended
May 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Income Tax Disclosure [Line Items]          
U.S. federal corporate tax rate   21.00% 21.00% 35.00%  
Tax Cuts and Jobs Act of 2017, accounting complete true or false     true   true
Transition tax expense       $ 600,000  
Final transition tax liability     $ 700,000   $ 700,000
Percentage of transition tax liability impact on effective tax rate     0.001    
Provisional tax benefit       3,400,000  
Final tax benefit   $ 0 $ 195,000 $ 3,418,000 3,600,000
Percentage of tax benefit from adjustment of deferred tax assets and liabilities   0.00% 0.20% 6.00%  
Deferred tax liability not recognized from undistributed earnings of foreign subsidiaries     $ 0   0
Deduction for dividends received in tax reform act     100.00%    
Dividends received from owned foreign corporations by us corporate shareholders     10.00%    
Foreign corporations shareholders holding period     1 year    
Amount of undistributed earnings of foreign subsidiaries for which deferred foreign withholding taxes not recorded     $ 21,100,000   21,100,000
Deferred tax assets, foreign operating loss carryforwards   $ 447,000 248,000   248,000
Deferred tax assets, valuation allowance   $ 755,000 169,000   169,000
Percentage of foreign net operating loss carryforward over indefinite period   28.00%      
Deferred tax assets       $ 21,100,000  
Deferred tax liabilities       $ 100,000  
Liability for interest and penalties   $ 1,400,000 1,000,000.0   1,000,000.0
Liability for uncertain tax position   $ 8,200,000 7,200,000   $ 7,200,000
Number of tax years   4 years      
IRC Section 382 Ownership Shift          
Income Tax Disclosure [Line Items]          
Disposal of deferred tax assets     7,400,000    
Reduction in deferred credit     6,900,000    
Net increase in tax expense     $ 500,000    
NephroGenex, Inc.          
Income Tax Disclosure [Line Items]          
Deferred tax assets $ 22,200,000        
Tax effected net operating losses 13,500,000        
Tax effected capitalized research and development expenses 8,500,000        
Tax effected federal tax credits 200,000        
Deferred tax liabilities $ 100,000        
Minimum          
Income Tax Disclosure [Line Items]          
Foreign net operating loss carryforwards expiration year   2020      
Maximum          
Income Tax Disclosure [Line Items]          
Foreign net operating loss carryforwards expiration year   2029      
U.S. State and Local          
Income Tax Disclosure [Line Items]          
Tax credits carryforward expiration year   2024      
Foreign Tax Authority          
Income Tax Disclosure [Line Items]          
Deferred tax assets, valuation allowance   $ 400,000